North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics | Association for Accessible Medicines
Register Now - Next Steps Workshop to explore the science, manufacturing & quality components of generics + biosimilars.

North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics

Statement of the Association for Accessible Medicines, Canadian Generic Pharmaceutical Association, and Mexican Association of Generic Medicines on the Announcement U.S.-Mexico Understanding on Biologic Exclusivity

The announced trade understanding between the U.S. and Mexico to extend brand name biologic data protection to ten years will harm patients who seek more affordable medicines. This provision would harm the growing biosimilar industry, which aims to provide price competition to some of the most expensive prescription drugs and allow patients to benefit from affordable medicines. The U.S., Mexico and Canada should reject these provisions, which would benefit brand name drug companies to the detriment of public health and the affordability of medical care.

MEDIA CONTACT:
Rachel Schwartz 
202.249.7147 (o)
202.251.8881 (c)

Issues

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.